The Conservative Alliance
Dear Reader,A rare government designation was recently issued to a leading “the race to a cure” ([link removed])(as seen in the image below)[link removed] ([link removed])The FDA hands out this rare classification “to provide lucrative incentives to the drug’s maker,” says NPR.And The Intercept says “the designation allows for the pharmaceutical company to profit exclusively for seven years from the product.”What does this mean for the stock?If history is any indication…This rare designation is responsible for helping Vertex’ launch from $35 to $235…[link removed] ([link removed])A 571% gain…And Alexion skyrocket from $22 to
$200…[link removed] ([link removed])That’s an 809% gain…Get the full breakdown of what this important designation could do to this new stock, by clicking here. ([link removed])Matt BenjaminSenior Macroeconomic Analyst, The Oxford ClubP.S. A critical data announcement is expected this month that could turboboost the stock to the moon.
Get the urgent details by clicking here. ([link removed])
If you don't want to receive this type of emails anymore, you can unsubscribe ([link removed]).
View our privacy policy ([link removed])
MATERIAL CONNECTION DISCLOSURE: You should assume that the sender of this email has an affiliate relationship and/or another material connection to the persons or businesses mentioned in this message and may receive commissions from purchases you make on subsequent web sites. You should not rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service.

The above message from our advertising sponsor. The products, views, and offerings made by advertisers are not necessarily endorsed by Us.

© 2020 The Conservative Alliance
Conservative Alliance Org
848 N. Rainbow Blvd. #3975 Las Vegas, NV 89107

You are subscribed to this email as [email protected]. Click here to modify your preferences [link removed] or unsubscribe [link removed].